Medical - Diagnostics & Research
Compare Stocks
5 / 10Stock Comparison
LH vs EXAS vs DGX vs NTRA vs ILMN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
LH vs EXAS vs DGX vs NTRA vs ILMN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $21.24B | $20.02B | $21.12B | $31.16B | $21.07B |
| Revenue (TTM) | $14.14B | $3.25B | $11.28B | $2.31B | $4.39B |
| Net Income (TTM) | $942M | $-208M | $1.02B | $-208M | $853M |
| Gross Margin | 27.8% | 69.7% | 33.2% | 64.8% | 67.1% |
| Operating Margin | 11.0% | -6.4% | 14.3% | -13.4% | 20.9% |
| Forward P/E | 14.5x | 582.8x | 17.8x | — | 26.8x |
| Total Debt | $7.20B | $2.52B | $6.92B | $214M | $2.55B |
| Cash & Equiv. | $532M | $956M | $420M | $1.08B | $1.42B |
LH vs EXAS vs DGX vs NTRA vs ILMN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Labcorp Holdings In… (LH) | 100 | 171.3 | +71.3% |
| Exact Sciences Corp… (EXAS) | 100 | 120.4 | +20.4% |
| Quest Diagnostics I… (DGX) | 100 | 161.3 | +61.3% |
| Natera, Inc. (NTRA) | 100 | 501.3 | +401.3% |
| Illumina, Inc. (ILMN) | 100 | 39.3 | -60.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LH vs EXAS vs DGX vs NTRA vs ILMN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LH ranks third and is worth considering specifically for value.
- Lower P/E (14.5x vs 26.8x)
EXAS is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 17.7%, EPS growth 80.3%, 3Y rev CAGR 15.9%
- Lower volatility, beta 0.12, current ratio 2.43x
- +96.9% vs LH's +6.1%
DGX has the current edge in this matchup, primarily because of its strength in income & stability and defensive.
- Dividend streak 15 yrs, beta 0.07, yield 1.6%
- Beta 0.07, yield 1.6%, current ratio 1.04x
- Beta 0.07 vs NTRA's 1.26
- 1.6% yield, 15-year raise streak, vs LH's 1.1%, (3 stocks pay no dividend)
NTRA is the clearest fit if your priority is long-term compounding.
- 20.9% 10Y total return vs DGX's 181.3%
- 35.9% revenue growth vs ILMN's -0.8%
ILMN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 19.4% margin vs NTRA's -9.0%
- 13.4% ROA vs NTRA's -10.6%, ROIC 16.8% vs -36.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.9% revenue growth vs ILMN's -0.8% | |
| Value | Lower P/E (14.5x vs 26.8x) | |
| Quality / Margins | 19.4% margin vs NTRA's -9.0% | |
| Stability / Safety | Beta 0.07 vs NTRA's 1.26 | |
| Dividends | 1.6% yield, 15-year raise streak, vs LH's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +96.9% vs LH's +6.1% | |
| Efficiency (ROA) | 13.4% ROA vs NTRA's -10.6%, ROIC 16.8% vs -36.1% |
LH vs EXAS vs DGX vs NTRA vs ILMN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
LH vs EXAS vs DGX vs NTRA vs ILMN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ILMN leads in 2 of 6 categories
LH leads 1 • NTRA leads 1 • DGX leads 1 • EXAS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ILMN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LH is the larger business by revenue, generating $14.1B annually — 6.1x NTRA's $2.3B. ILMN is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to NTRA's -9.0%. On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14.1B | $3.2B | $11.3B | $2.3B | $4.4B |
| EBITDAEarnings before interest/tax | $2.2B | -$41M | $1.9B | -$310M | $1.1B |
| Net IncomeAfter-tax profit | $942M | -$208M | $1.0B | -$208M | $853M |
| Free Cash FlowCash after capex | $1.4B | $357M | $1.3B | $97M | $989M |
| Gross MarginGross profit ÷ Revenue | +27.8% | +69.7% | +33.2% | +64.8% | +67.1% |
| Operating MarginEBIT ÷ Revenue | +11.0% | -6.4% | +14.3% | -13.4% | +20.9% |
| Net MarginNet income ÷ Revenue | +6.7% | -6.4% | +9.1% | -9.0% | +19.4% |
| FCF MarginFCF ÷ Revenue | +9.8% | +11.0% | +11.8% | +4.2% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.8% | +23.1% | +9.2% | +39.8% | +4.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +32.9% | +90.4% | +15.5% | +185.4% | +6.1% |
Valuation Metrics
LH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 21.8x trailing earnings, DGX trades at a 14% valuation discount to ILMN's 25.5x P/E. On an enterprise value basis, LH's 12.7x EV/EBITDA is more attractive than ILMN's 19.6x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $21.2B | $20.0B | $21.1B | $31.2B | $21.1B |
| Enterprise ValueMkt cap + debt − cash | $27.9B | $21.6B | $27.6B | $30.3B | $22.2B |
| Trailing P/EPrice ÷ TTM EPS | 24.67x | -95.37x | 21.81x | -144.62x | 25.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.45x | 582.83x | 17.77x | — | 26.77x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 6.01x |
| EV / EBITDAEnterprise value multiple | 12.70x | — | 12.71x | — | 19.58x |
| Price / SalesMarket cap ÷ Revenue | 1.52x | 6.16x | 1.91x | 13.51x | 4.86x |
| Price / BookPrice ÷ Book value/share | 2.50x | 8.24x | 2.96x | 17.55x | 7.95x |
| Price / FCFMarket cap ÷ FCF | 17.61x | 56.10x | 15.54x | 285.53x | 22.63x |
Profitability & Efficiency
ILMN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-15 for NTRA. NTRA carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs NTRA's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +10.9% | -8.7% | +13.8% | -15.3% | +32.8% |
| ROA (TTM)Return on assets | +5.1% | -3.5% | +6.3% | -10.6% | +13.4% |
| ROICReturn on invested capital | +7.8% | -3.6% | +8.8% | -36.1% | +16.8% |
| ROCEReturn on capital employed | +9.9% | -4.0% | +11.5% | -18.3% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 7 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.83x | 1.05x | 0.95x | 0.13x | 0.94x |
| Net DebtTotal debt minus cash | $6.7B | $1.6B | $6.5B | -$862M | $1.1B |
| Cash & Equiv.Liquid assets | $532M | $956M | $420M | $1.1B | $1.4B |
| Total DebtShort + long-term debt | $7.2B | $2.5B | $6.9B | $214M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 6.22x | -5.47x | 6.26x | -25.21x | 12.09x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $3,717 for ILMN. Over the past 12 months, EXAS leads with a +96.9% total return vs LH's +6.1%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs ILMN's -10.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.8% | +3.1% | +10.8% | -3.9% | +3.2% |
| 1-Year ReturnPast 12 months | +6.1% | +96.9% | +9.9% | +37.3% | +81.7% |
| 3-Year ReturnCumulative with dividends | +39.4% | +53.0% | +48.5% | +314.0% | -27.1% |
| 5-Year ReturnCumulative with dividends | +12.6% | +0.4% | +47.7% | +115.9% | -62.8% |
| 10-Year ReturnCumulative with dividends | +150.7% | +1669.1% | +181.3% | +2089.4% | +0.7% |
| CAGR (3Y)Annualised 3-year return | +11.7% | +15.2% | +14.1% | +60.6% | -10.0% |
Risk & Volatility
Evenly matched — EXAS and DGX each lead in 1 of 2 comparable metrics.
Risk & Volatility
DGX is the less volatile stock with a 0.07 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs NTRA's 85.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.52x | 0.12x | 0.07x | 1.26x | 1.23x |
| 52-Week HighHighest price in past year | $293.72 | $104.98 | $213.50 | $256.36 | $155.53 |
| 52-Week LowLowest price in past year | $239.67 | $38.81 | $164.65 | $131.81 | $73.86 |
| % of 52W HighCurrent price vs 52-week peak | +87.9% | +99.9% | +89.4% | +85.7% | +89.2% |
| RSI (14)Momentum oscillator 0–100 | 40.3 | 76.4 | 40.1 | 57.1 | 65.2 |
| Avg Volume (50D)Average daily shares traded | 579K | 4.2M | 841K | 1.3M | 1.5M |
Analyst Outlook
DGX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LH as "Buy", EXAS as "Buy", DGX as "Hold", NTRA as "Buy", ILMN as "Buy". Consensus price targets imply 20.7% upside for LH (target: $311) vs -1.6% for EXAS (target: $103). For income investors, DGX offers the higher dividend yield at 1.64% vs LH's 1.11%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $311.33 | $103.18 | $220.57 | $262.50 | $147.38 |
| # AnalystsCovering analysts | 35 | 41 | 34 | 27 | 50 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | — | +1.6% | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | 15 | — | — |
| Dividend / ShareAnnual DPS | $2.87 | — | $3.12 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.1% | +0.1% | +2.1% | 0.0% | +3.5% |
ILMN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LH leads in 1 (Valuation Metrics). 1 tied.
LH vs EXAS vs DGX vs NTRA vs ILMN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LH or EXAS or DGX or NTRA or ILMN a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Labcorp Holdings Inc. (LH) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LH or EXAS or DGX or NTRA or ILMN?
On trailing P/E, Quest Diagnostics Incorporated (DGX) is the cheapest at 21.
8x versus Illumina, Inc. at 25. 5x. On forward P/E, Labcorp Holdings Inc. is actually cheaper at 14. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — LH or EXAS or DGX or NTRA or ILMN?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -62. 8% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus ILMN's +0. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LH or EXAS or DGX or NTRA or ILMN?
By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.
07β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 1613% more volatile than DGX relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — LH or EXAS or DGX or NTRA or ILMN?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 35. 9% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LH or EXAS or DGX or NTRA or ILMN?
Illumina, Inc.
(ILMN) is the more profitable company, earning 19. 6% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LH or EXAS or DGX or NTRA or ILMN more undervalued right now?
On forward earnings alone, Labcorp Holdings Inc.
(LH) trades at 14. 5x forward P/E versus 582. 8x for Exact Sciences Corporation — 568. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LH: 20. 7% to $311. 33.
08Which pays a better dividend — LH or EXAS or DGX or NTRA or ILMN?
In this comparison, DGX (1.
6% yield), LH (1. 1% yield) pay a dividend. EXAS, NTRA, ILMN do not pay a meaningful dividend and should not be held primarily for income.
09Is LH or EXAS or DGX or NTRA or ILMN better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LH and EXAS and DGX and NTRA and ILMN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LH is a mid-cap quality compounder stock; EXAS is a mid-cap high-growth stock; DGX is a mid-cap quality compounder stock; NTRA is a mid-cap high-growth stock; ILMN is a mid-cap quality compounder stock. LH, DGX pay a dividend while EXAS, NTRA, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.